Heart attacks don’t just end when you leave the hospital. For many, the inflammation that triggered the attack keeps smoldering—quietly setting the stage for another one. Abcentra believes it’s time to put that fire out.
The Milestone: First Patient Dosed in FORTIFY Trial
Abcentra LLC just dosed the first patient in FORTIFY, a Phase 2b trial testing orticumab—their experimental therapy for cardiovascular inflammation after type 1 myocardial infarction (MI).
Why this matters:
- Cardiovascular inflammation is a root cause of recurrent heart attacks.
- Current treatments focus on cholesterol but don’t fully address plaque inflammation.
- Orticumab targets the problem locally inside atherosclerotic plaques.
How the FORTIFY Study Works?
Study name: FORTIFY (NCT06927739) – Focused Orticumab Research for Treating Inflammation in Coronary Arteries
Design highlights:
- Multi-center, randomized, placebo-controlled, double-blind
- 40 sites in the US, UK, and Europe
- 240 patients with prior type 1 MI and high coronary inflammation
- Two orticumab dose arms vs. two placebo arms
- Treatment: 24 weeks
Primary goal:
- Reduce Fat Attenuation Index (FAI) scores at Week 24 using coronary CT angiography (CCTA).
Why FAI Scoring Is a Big Deal
FAI is an advanced imaging biomarker. It offers a “window” into coronary artery inflammation—a key predictor of major adverse cardiovascular events.
Dr. Peter Libby, board member and cardiovascular researcher, explains:
“By using cutting-edge imaging, we can see if orticumab truly reduces the inflammation driving heart attack risk.”
What Makes Orticumab Different
Orticumab is a monoclonal antibody targeting oxidized LDL. That means it works differently than standard cholesterol-lowering drugs:
- Goes beyond lowering LDL numbers.
- Directly inhibits inflammation inside vulnerable plaques.
- Could help prevent recurring heart attacks.
CEO Christopher Farina says:
“We’re aiming to significantly reduce cardiovascular risk on top of current care by targeting inflammation at the source.”
The Bigger Picture
Cardiovascular disease remains the world’s leading killer. If FORTIFY proves successful, orticumab could:
- Redefine secondary prevention in heart disease.
- Give doctors a targeted way to calm dangerous plaque inflammation.
- Complement existing cholesterol-lowering strategies.
Chairman John Farina calls the trial:
“A major step forward for the cardiovascular field and a potentially transformative therapy.”
